You are viewing the site in preview mode

Skip to main content
Fig. 2 | The Journal of Headache and Pain

Fig. 2

From: Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

Fig. 2

Reduction in mean monthly migraine days by (a) 12-week dosing interval and (b) 4-week interval (efficacy population). *P < 0.001 vs placebo. †Nominal P < 0.001 vs placebo (analyses of monthly migraine days over weeks 13–24 were not formally tested per the predefined statistical hierarchy)

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us